Highlights

• Electroacupuncture treatment of diabetic peripheral neuropathy (DPN) reduced cell apoptosis of sciatic nerves in diabetic rats, inhibited the occurrence of endoplasmic reticulum stress, and thus prevented sciatic nerve injuries.
• The treatment effectiveness of electroacupuncture for DPN may be mediated via downregulation of glucose-related protein 78 (GRP78) and caspase-12.

Highlights

• Diabetic kidney disease is a common comorbidity of type 2 diabetes mellitus.
• In studies investigating the effect of renal function on the efficacy of treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs), these agents improved glycemic control in patients with mild to moderately impaired kidney function, without significant differences compared with patients with normal renal function.
• GLP-1RAs were associated with a lower incidence of diabetic nephropathy, mostly driven by a reduction in albuminuria, compared with placebo in several large cardiovascular outcome trials.

Highlights

• This study suggests that basal insulin-supported oral antidiabetic drugs (OADs) therapy is superior to OADs alone in preventing diabetic retinopathy.
• This will help clinicians to select a suitable subsequent therapy after initial intensive insulin therapy.

Highlights

• This study demonstrates that of brown adipose tissue (BAT) with CL316,243 attenuates the progress of diabetic kidney disease (DKD).
• Mechanistically, the activation of BAT improved concentrations of circulating adipokines and microRNAs, which further affected the diabetic kidney and reactivated the AMP-activated protein kinase/sirtuin 1/peroxisome proliferator-activated receptor-γ coactivator-1α signaling pathway.
• The data suggest that BAT activation could be a novel therapeutic approach in the treatment of DKD.

Highlights

• This post hoc analysis of the GetGoal-O trial suggests that add-on therapy with lixisenatide in non-frail patients aged ≥70 years with type 2 diabetes uncontrolled on basal insulin is safe and well tolerated and should be considered in this patient population as an alternative to rapid-acting insulin. A fixed-ratio combination of lixisenatide and insulin glargine U100 (iGlarLixi) is available.
• The results suggest similar efficacy for lixisenatide in patients with moderate renal insufficiency without dose adjustment, with monitoring always advisable in this population

Highlights

• Saxagliptin significantly increased the bile acid pool.
• Type 2 diabetes (T2D) patients with overweight/obesity exhibited greater improvement in glycemic control and additional metabolic benefits after saxagliptin treatment.
• Deoxycholic acid (DCA) and glycodeoxycholic acid (GDCA) showed a strong correlation with improvements in metabolic indicators in the overweight/obesity group, suggesting that DDCA and GDCA may be involved in the beneficial effects of saxagliptin in overweight and obese drug-naïve T2D patients.

Highlights

• Type 2 diabetes (T2D) is an independent predictor of survival and recurrence after surgery in patients with renal cell carcinoma (RCC).
• This finding reveals the importance of T2D in determining the prognosis of patients with RCC.

Highlights

• Type 1 diabetes onset age in Kumasi/Ghana has a peak at around 17 to 20 years, whereas the peak is at 11 to 12 years in North Rhine-Westphalia, Germany.
• Higher proportions of females were found in the type 1 diabetes cohort from Ghana, and males were more frequent in the German cohort.